Xintela AB

Equities

XINT

SE0007756903

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 16:10:34 28/05/2024 BST			5-day change	1st Jan Change
0.262 ^SEK	+0.77%		+4.38%	-3.32%

05-24	Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-23	Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses	CI

Xintela AB Appoints Per Norlén as Chief Medical Officer from 1 July 2021

May 04, 2021 at 05:55 am

Xintela AB (publ) announced that Per Norlén will also have the role of Xintelas Chief Medical Officer (CMO) from 1 July 2021. Per Norlén is a physician, board certified in clinical pharmacology, with extensive research experience and 20 years of experience from early phase clinical drug development. Most recently he was CEO and before that CMO at Alligator Bioscience AB.

Latest news about Xintela AB

Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-24	CI
Xintela and EQGen Biomedical to Collaborate to Develop EQSTEM Stem Cell Treatment for Horses	05-23	CI
Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-28	CI
Xintela Names New Chief Scientific Officer	02-20	MT
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	02-19	CI
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	12-21	CI
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	12-20	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-24	CI
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	13/10/23	CI
Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
Xintela Receives Product Patent in USA for Chondrocyte-Based Products	15/08/23	CI
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study	22/06/23	CI
Xintela AB Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress	01/06/23	CI
Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23	CI
Xintela AB Initiates Last Dose Level in Knee Osteoarthritis Study	02/05/23	CI
Xintela Starts Last Dose Level of Xstem in Knee Osteoarthritis Clinical Study	13/04/23	CI
Xintela AB Completes Dosing of XSTEM Second Dose Level in Knee Osteoarthritis Clinical Study	03/03/23	CI
Xintela AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	24/02/23	CI
Xintela and Northx Biologics Sign Collaboration Framework Agreement	14/12/22	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/11/22	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/11/22	CI
Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study	09/11/22	CI
Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study	30/09/22	CI
Xintela AB Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022	22/09/22	CI
Xintela AB Starts Clinical Study with XSTEM for Difficult-To-Heal Leg Ulcers	20/09/22	CI

Chart Xintela AB

Duration

Period

More charts

Company Profile

Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

Sector

Biotechnology & Medical Research

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XINTELA AB	-3.32%	13.89M
MODERNA, INC.	+51.38%	63.85B
IQVIA HOLDINGS INC.	-2.32%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.32%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.49%	18.69B
BIO-TECHNE CORPORATION	+2.77%	12.73B
UNITED THERAPEUTICS CORPORATION	+21.44%	12.11B
MEDPACE HOLDINGS, INC.	+27.84%	12.07B

Other Biotechnology & Medical Research